**AI生物标志物分析公司Nucleai完成1400万美元B+轮融资，引领病理学研究新方向**
以色列AI空间生物标志物分析初创公司Nucleai近日宣布，成功获得了1400万美元的B+轮融资，此轮融资由知名投资机构M Ventures领投。Nucleai的现有投资者，包括Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel以及Grove Ventures等，也积极参与了本轮融资。
Nucleai致力于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以期预测疾病的治疗效果。这一创新方法有望革新病理学研究领域，提高疾病诊断的精确性和治疗方案的个性化程度。
公司创始人表示，本轮融资的资金将主要用于进一步开发其AI平台，加强研究和开发能力，以及扩大市场影响力。Nucleai的技术突破，不仅将对医学研究产生深远影响，也为未来的精准医疗提供了强有力的支持。
Nucleai的成功融资和技术创新，展示了AI在医疗领域日益重要的角色，以及投资者对这一领域持续增长的信心。随着科技的不断进步，我们有理由期待AI将为生物医学研究和临床实践带来更多的突破性成果。
英语如下：
**News Title:** Nucleai Secures $14M in B+ Round, Pioneering Revolution in Spatial Biomarker Analysis in AI Healthcare
**Keywords:** AI生物分析, Nucleai funding, pathology image recognition
**News Content:**
**AI-driven biomarker analysis company Nucleai closes $14 million B+ funding round, ushering in a new era in pathology research**
Israeli AI startup Nucleai, specializing in spatial biomarker analysis, recently announced that it has successfully raised $14 million in its B+ funding round, led by prominent investor M Ventures. Existing backers, including Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures, also participated in this round.
Nucleai focuses on leveraging artificial intelligence and machine learning to perform in-depth analysis of病理 images and spatial data at the cellular and tissue levels, aiming to predict disease treatment outcomes. This innovative approach has the potential to revolutionize the field of pathology, enhancing diagnostic accuracy and personalization of treatment plans.
The company’s founders stated that the fresh funding will be allocated to further develop their AI platform, strengthen R&D capabilities, and expand market presence. Nucleai’s technological advancements are not only set to have a profound impact on medical research but also provide robust support for precision medicine in the future.
Nucleai’s successful funding and innovation highlight the growing significance of AI in the healthcare sector and investors’ continued confidence in its potential. With ongoing technological advancements, we can anticipate more breakthrough achievements in biomedical research and clinical practice facilitated by AI.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1